CANNABINOID REC1; RBX-50UG

Analysis Note

ControlBrain tissue

Application

Research CategoryNeuroscience

Research Sub CategoryNeuroinflammation & PainNeurotransmitters & Receptors

Western blot: 1-10 µg/mL using ECL. Expected sizes are ~60kDa and 80-84kDa under reducing conditions.

ELISA: 1:10,000-1:100,000 using 50-100 ng control peptide (Cat. No. AG357) per well.

Optimal working dilutions must be determined by the end user.

This Anti-Cannabinoid Receptor 1 Antibody, N-terminus is validated for use in ELISA, WB for the detection of Cannabinoid Receptor 1.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Immunogen

A 14 amino acid N-terminus peptide sequence (aa 1-14) (Gerard et al. 1991; Gerard et al.

1990; Shire et al. 1995; Matsuda et al. 1990; Ho et al. 1996; Chakraborty et al. 1995).

Epitope: N-terminus

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Physical form

ImmunoAffinity Purified

Affinity Purified immunoglobulin. Liquid in 100mM Tris, pH 7.5, containing 0.2% BSA and 0.05% sodium azide.

Specificity

Recognizes human Cannabinoid Receptor 1 (CB1). The immunogen shows no significant sequence homology with CB2 or other receptors.

Storage and Stability

Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Target description

~60kDa and 80-84kDa